Prognostic and therapeutic significance of myeloma genetics and gene expression profiling

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Molecular diagnostic tools and novel therapeutics now offer the potential for accurate prognostic and personalized treatment road maps for patients with multiple myeloma (MM). We will review the evidence and provide specific recommendations for routine clinical molecular genetic testing and use of such information to guide therapeutic decision making. In particular, the negative prognostic impact of specific IgH translocations such as the t(4;14), t(14;16), chromosome 13 deletion by conventional cytogenetics and loss of 17p13 by interphase fluorescence in situ hybridization are now established. Preliminary gene expression profiling studies have also demonstrated that individual genes (CSK1-B) or groups of genes can define prognosis with greater accuracy than conventional genetic markers and can provide pharmacogenomic and biologic insight into the pathophysiology, therapeutics, and future targets of myeloma. Importantly, we recommend that all clinical trials now adopt routine genetic testing and risk stratification.

Original languageEnglish (US)
Pages (from-to)6339-6344
Number of pages6
JournalJournal of Clinical Oncology
Volume23
Issue number26
DOIs
StatePublished - 2005

Fingerprint

Gene Expression Profiling
Genetic Testing
Chromosomes, Human, Pair 13
Chromosome Deletion
Molecular Pathology
Pharmacogenetics
Interphase
Therapeutics
Multiple Myeloma
Fluorescence In Situ Hybridization
Genetic Markers
Cytogenetics
Genes
Molecular Biology
Decision Making
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{5b4a82e4395844b288f2dbd2ac56e219,
title = "Prognostic and therapeutic significance of myeloma genetics and gene expression profiling",
abstract = "Molecular diagnostic tools and novel therapeutics now offer the potential for accurate prognostic and personalized treatment road maps for patients with multiple myeloma (MM). We will review the evidence and provide specific recommendations for routine clinical molecular genetic testing and use of such information to guide therapeutic decision making. In particular, the negative prognostic impact of specific IgH translocations such as the t(4;14), t(14;16), chromosome 13 deletion by conventional cytogenetics and loss of 17p13 by interphase fluorescence in situ hybridization are now established. Preliminary gene expression profiling studies have also demonstrated that individual genes (CSK1-B) or groups of genes can define prognosis with greater accuracy than conventional genetic markers and can provide pharmacogenomic and biologic insight into the pathophysiology, therapeutics, and future targets of myeloma. Importantly, we recommend that all clinical trials now adopt routine genetic testing and risk stratification.",
author = "Stewart, {Alexander Keith} and Rafael Fonseca",
year = "2005",
doi = "10.1200/JCO.2005.05.023",
language = "English (US)",
volume = "23",
pages = "6339--6344",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "26",

}

TY - JOUR

T1 - Prognostic and therapeutic significance of myeloma genetics and gene expression profiling

AU - Stewart, Alexander Keith

AU - Fonseca, Rafael

PY - 2005

Y1 - 2005

N2 - Molecular diagnostic tools and novel therapeutics now offer the potential for accurate prognostic and personalized treatment road maps for patients with multiple myeloma (MM). We will review the evidence and provide specific recommendations for routine clinical molecular genetic testing and use of such information to guide therapeutic decision making. In particular, the negative prognostic impact of specific IgH translocations such as the t(4;14), t(14;16), chromosome 13 deletion by conventional cytogenetics and loss of 17p13 by interphase fluorescence in situ hybridization are now established. Preliminary gene expression profiling studies have also demonstrated that individual genes (CSK1-B) or groups of genes can define prognosis with greater accuracy than conventional genetic markers and can provide pharmacogenomic and biologic insight into the pathophysiology, therapeutics, and future targets of myeloma. Importantly, we recommend that all clinical trials now adopt routine genetic testing and risk stratification.

AB - Molecular diagnostic tools and novel therapeutics now offer the potential for accurate prognostic and personalized treatment road maps for patients with multiple myeloma (MM). We will review the evidence and provide specific recommendations for routine clinical molecular genetic testing and use of such information to guide therapeutic decision making. In particular, the negative prognostic impact of specific IgH translocations such as the t(4;14), t(14;16), chromosome 13 deletion by conventional cytogenetics and loss of 17p13 by interphase fluorescence in situ hybridization are now established. Preliminary gene expression profiling studies have also demonstrated that individual genes (CSK1-B) or groups of genes can define prognosis with greater accuracy than conventional genetic markers and can provide pharmacogenomic and biologic insight into the pathophysiology, therapeutics, and future targets of myeloma. Importantly, we recommend that all clinical trials now adopt routine genetic testing and risk stratification.

UR - http://www.scopus.com/inward/record.url?scp=27244439379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27244439379&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.05.023

DO - 10.1200/JCO.2005.05.023

M3 - Article

VL - 23

SP - 6339

EP - 6344

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 26

ER -